The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Relay Therapeutics Inc shares valued at $32,217 were sold by Rahmer Peter on Apr 30 ’25. At $3.00 per share, Rahmer Peter sold 10,739 shares. The insider’s holdings dropped to 390,081 shares worth approximately $1.11 million following the completion of this transaction.
Also, Rahmer Peter sold 1,364 shares, netting a total of over 4,324 in proceeds. Following the sale of shares at $3.17 each, the insider now holds 400,820 shares.
Before that, Catinazzo Thomas had sold 12,943 shares from its account. In a trade valued at $38,829, the Chief Financial Officer traded Relay Therapeutics Inc shares for $3.00 each. Upon closing the transaction, the insider’s holdings decreased to 12,943 shares, worth approximately $1.01 million.
As published in their initiating research note from Wells Fargo on April 17, 2025, Relay Therapeutics Inc [RLAY] has been an Equal weight and the price target has been revised to $4. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in early September. Earlier on September 10, 2024, Oppenheimer downgraded its rating. Their new recommendation was “a Perform” for RLAY stock which previously was a “an Outperform”.
Analyzing RLAY Stock Performance
During the last five days, there has been a surge of approximately 1.97%. Over the course of the year, Relay Therapeutics Inc shares have dropped approximately -30.95%. Shares of the company reached a 52-week high of $5.99 on 01/10/25 and a 52-week low of $1.77 on 04/07/25.
Support And Resistance Levels for Relay Therapeutics Inc (RLAY)
According to the 24-hour chart, there is a support level at 2.77, which, if violated, would cause prices to drop to 2.69. In the upper region, resistance lies at 2.96. The next price resistance is at 3.07. RSI (Relative Strength Index) is 46.33 on the 14-day chart, showing neutral technical sentiment.
